Yasuo Imai

Dr. Yasuo Imai

Department of Diagnostic Pathology, Ota Memorial Hospital, Gunma, Japan
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
Yasuo ImaiYasuo Imai
Yasuo Imai
SASakiyo Asada
Sakiyo Asada
STSatomi Tsukahara
Satomi Tsukahara
EIEtsuko Ishikawa
Etsuko Ishikawa
TTTakashi Tsuruo
Takashi Tsuruo
YSYoshikazu Sugimoto
Yoshikazu Sugimoto
Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer reagents such as mitoxantrone, 7-ethyl-10-hydroxycamptothecin, and topotecan. We reported previously that estrone and 17β-estradiol reverse BCRP-mediated multidrug resistance. In the present study, we demonstrate that BCRP exports estrogen metabolites. First, we generated BCRP-transduced LLC-PK1 (LLC/BCRP) cells, in which exogenous BCRP is expressed in the apical membrane, and investigated transcellular transport of 3H-labeled compounds using cells plated on microporous filter membranes. The basal-to-apical transport (excretion) of mitoxantrone, estrone, and 17β-estradiol was greater in LLC/BCRP cells than in LLC-PK1 cells. Thin-layer chromatography of transported steroids revealed that the transport of estrone and 17β-estradiol was independent of BCRP expression. Alternatively, increased excretion of estrone sulfate and 17β-estradiol sulfate was observed in LLC/BCRP cells. BCRP inhibitors completely inhibited the increased excretion of sulfated estrogens across the apical membrane. Conversion of estrogens into their sulfate conjugates was similar between LLC/BCRP and LLC-PK1 cells, suggesting that the increased excretion of estrogen sulfates was attributable to BCRP-mediated transport. Next, the uptake of 3H-labeled compounds in membrane vesicles from BCRP-transduced K562 (K562/BCRP) cells was investigated. 3H-labeled estrone sulfate, but not 3H-labeled estrone or 17β-estradiol, was taken up by membrane vesicles from K562/BCRP cells, and this was ATP-dependent. Additionally, BCRP inhibitors suppressed the transport of estrone sulfate in membrane vesicles from K562/BCRP cells. These results suggest that BCRP does not transport either free estrone or 17β-estradiol but exports sulfate conjugates of these estrogens.

6 January 2016 in Chinese Journal of Cancer
Verified
Journal Article
Open access
PDF file
HYHidetsugu Yamagishi
Hidetsugu Yamagishi
HKHajime Kuroda
Hajime Kuroda
Yasuo ImaiYasuo Imai
Yasuo Imai
HHHideyuki Hiraishi
Hideyuki Hiraishi
Colorectal cancer (CRC) results from the progressive accumulation of genetic and epigenetic alterations that lead to the transformation of normal colonic mucosa to adenocarcinoma. Approximately 75% of CRCs are sporadic and occur in people without genetic predisposition or family history of CRC. During the past two decades, sporadic CRCs were classified into three major groups according to frequently altered/mutated genes. These genes have been identified by linkage analyses of cancer-prone families and by individual mutation analyses of candidate genes selected on the basis of functional data. In the first half of this review, we describe the genetic pathways of sporadic CRCs and their clinicopathologic features. Recently, large-scale genome analyses have detected many infrequently mutated genes as well as a small number of frequently mutated genes. These infrequently mutated genes are likely described in a limited number of pathways. Gene-oriented models of CRC progression are being replaced by pathway-oriented models. In the second half of this review, we summarize the present knowledge of this research field and discuss its prospects.

1 June 2002
Verified
Journal Article
Closed access
Yasuo ImaiYasuo Imai
Yasuo Imai
MNMinoru Nakane
Minoru Nakane
KKKumie Kage
Kumie Kage
STSatomi Tsukahara
Satomi Tsukahara
EIEtsuko Ishikawa
Etsuko Ishikawa
YSYoshikazu Sugimoto
Yoshikazu Sugimoto

15 January 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
Yasuo ImaiYasuo Imai
Yasuo Imai
EIEtsuko Ishikawa
Etsuko Ishikawa
SASakiyo Asada
Sakiyo Asada
YSYoshikazu Sugimoto
Yoshikazu Sugimoto
Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. We previously reported that BCRP transports sulfated estrogens. In the present study, we show that at physiologic levels, estrogens markedly decrease endogenous BCRP expression in the estrogen-responsive and estrogen receptor α (ERα)–positive human breast cancer MCF-7 cells, but not in estrogen-nonresponsive human cancer cells. 17 β-Estradiol (E2) also significantly reduces exogenous BCRP expression, driven by a constitutive promoter, in BCRP-transduced estrogen-responsive and ERα-positive MCF-7 (MCF-7/BCRP) and T-47D cells, but not in BCRP-transduced estrogen-nonresponsive MDA-MB-231 and SKOV-3 cells. E2 potentiates the cytotoxicity of SN-38, but not vincristine, in MCF-7/BCRP cells significantly, and increases cellular topotecan uptake in MCF-7 and MCF-7/BCRP cells. Antiestrogen tamoxifen partially reverses E2-mediated BCRP down-regulation in MCF-7 and MCF-7/BCRP cells and treatment of MCF-7/BCRP cells with an ERα small interfering RNA abolished E2-mediated BCRP down-regulation, suggesting that interaction of E2 and ERα is necessary for BCRP down-regulation. E2 does not affect endogenous BCRP mRNA levels in MCF-7 cells or exogenous BCRP mRNA levels in MCF-7/BCRP cells. The results from pulse-chase labeling experiments with MCF-7/BCRP cells suggest that decreased protein biosynthesis and maturation, but not alterations in protein turnover, might underlie E2-mediated BCRP down-regulation. These data indicate that estrogen down-regulates BCRP expression by novel posttranscriptional mechanisms. This is the first report of small molecules that can affect BCRP protein expression in cells and may therefore assist in establishing new strategies for regulating BCRP expression.

1 December 2000 in Hepatology
Verified
Journal Article
Open access
PDF file
YKYukihiro Koike
Yukihiro Koike
YSYasushi Shiratori
Yasushi Shiratori
SSShinpei Sato
Shinpei Sato
SOShuntaro Obi
Shuntaro Obi
TTTakuma Teratani
Takuma Teratani
MOMasao Omata
Masao Omata
Patients with hepatocellular carcinoma (HCC) frequently experience intrahepatic HCC recurrence even after complete ablation of primary lesions. Because the oncogenic process may be different for hepatitis B viral (B–viral) and hepatitis C viral (C–viral) HCC, the present study was conducted to elucidate the factors contributing to HCC recurrence with respect to the infected hepatitis virus. Two hundred thirty–six patients with a single HCC lesion who underwent complete ablation of the tumor by PEIT and/or PMCT or surgical resection at Tokyo University and its affiliated hospitals from 1993 to 1997 were enrolled. The patients were classified into 3 groups: the B–viral group, C–viral group, and NBNC group. After complete removal of tumors, the patients were followed for a mean period of 39 months. The factors contributing to HCC recurrence were analyzed by univariate and multivariate analysis using the Cox proportional hazard model. The rate of intrahepatic recurrence in enrolled patients at 1, 3, and 5 years was 19%, 50%, and 64%, respectively. The intrahepatic recurrence rate in C–viral and B–viral HCC was higher than that in the NBNC–related HCC. Fibrosis staging, pathological grading of HCC, and serum AFP levels were significantly linked to intrahepatic recurrence by univariate analysis, and fibrosis staging was strongest in the multivariate analysis for C–viral HCC (P = .004). In contrast, fibrosis staging did not affect the recurrence in B–viral (P = .51) and NBNC–related (P = .77) HCC. Risk factors for HCC recurrence differed according to the infected viral state.

1 January 2001 in Clinical and Diagnostic Laboratory Immunology
Verified
Journal Article
Open access
PDF file
TITsuneo Ikenoue
Tsuneo Ikenoue
SMShin Maeda
Shin Maeda
KOKeiji Ogura
Keiji Ogura
MAMasao Akanuma
Masao Akanuma
YMYuzo Mitsuno
Yuzo Mitsuno
MOMasao Omata
Masao Omata
Nucleic acid amplification was performed for five loci in the cag pathogenicity island (PAI) of Helicobacter pylori (comprising cagA , the cagA promoter region, cagE , cagT , and the left end of cag II [LEC]), and gastric inflammation in patients was evaluated. Of 204 H. pylori isolates from Japanese patients (53 with peptic ulcer, 55 with gastric cancer, and 96 with chronic gastritis), 197 (96.6%) were positive for all five loci. Two isolates (1%) were negative for all five loci, and five isolates (2.4%) were positive for only cagA and LEC. These latter seven isolates were all from patients with mild chronic gastritis. Neutrophil infiltration in gastric mucosa was significantly milder in patients infected with partially or totally deleted-PAI strains than in those with intact-PAI strains. The cagE gene was a more accurate marker of an intact cag PAI than the cagA gene, and cagE seemed to be more useful in discriminating between H. pylori strains causing different rates of disease progression.